drugset / Trial / NCT00940914

Dopaminergic Loss and Pain in Parkinson's Disease

NCT00940914 ↗

Phase 2 Completed 20 enrolled University Hospital, Toulouse
Non-randomizedParallel-groupOpen-labelBasic science

Summary

About 46% of patients suffering from Parkinson's disease present pain disorders. Parkinson disease is characterized by loss of dopaminergic neurons. The aim of this study is to assess the relationship between the loss of dopaminergic neurons and the existence of pain in Parkinson's disease. Using single photon emission computerized tomography (SPECT) imaging (123I FP-CIT, which binds dopamine transporter) and the determination of subjective pain threshold, the investigators will establish correlations between dopaminergic degeneration and pain perception.

Timeline

Start
2009-03
Primary completion
2010-03
Completion
2010-07

Drugs

EvaluationDrugModalityDoseRoute
Subject ioflupane 123I Unknown 2.5 ml Intravenous

Indications